Hyperhomocysteinemia: Detection, risk assessment, and treatment

Current Opinion in Nephrology and Hypertension

Volumn 6, Issue 5, 1997, Pages 483-488

  Dennis, Vincent W ^a   Nurko, Saul ^a   Robinson, Killian ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOLIC ACID;

ATHEROSCLEROSIS; AUTOSOMAL RECESSIVE DISORDER; CHRONIC KIDNEY FAILURE; DISEASE ASSOCIATION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; HYPERHOMOCYSTEINEMIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0030929483     PISSN: 10624821     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041552-199709000-00013     Document Type: Review

References (48)

1. Mayer EM, Jacobsen DW, Robinson K: Homocysteine and coronary atherosclerosis. J Am Coll Cardiol 1996, 27:517-527.
2. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. J Am Med Assoc 1995, 274:1049-1057.
3. Dennis VW, Robinson K: Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int 1997, 50(suppl):S11-S17.
4. Kang SS, Wong PW: Genetic and nongenetic factors for moderate hyperhomocyst(e)inemia. Atherosclerosis 1996, 119:135-138. Hyperhomocysteinemia can be classified as moderate, intermediate or severe, on the basis of the basal homocysteine level. A single genetic defect without a second one or a nongenetic factor (e.g. folic acid deficiency) might not be sufficient to produce overt hyperhomocysteinemia. A genetic defect might be essential for persistent hyperhomocysteinemia.
5. McCully KS: Homocysteine and vascular disease. Nature Med 1996, 2:386-389.
6. Mudd SH, Levy HL: Plasma homocyst(e)ine or homocysteine? [Letter]. N Engl J Med 1995, 333:325.
7. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland PM, Kvale G: Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. J Am Med Assoc 1995, 274:1526-1533.
8. Malinow MR, Kang SS, Taylor LM, Wong PWK, Coull B, Inahara T, Mukerjee D, Sexton G, Upson B: Prevalence of hyperhomocyst(e)inemia in patients with peripheral arterial occlusive disease. Circulation 1989, 79:1180-1188.
9. Stampfer MJ, Malinow MR, Willett WC, Newcomer LM, Upson B, Ullmann D, Tishler PV, Hennekens CH: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. J Am Med Assoc 1992, 268:877-881.
10. Bostom AG, Shemin D, Lapane KL, Miller JW, Sutherland P, Nadeau M, Seyoum E, Hartman W, Prior R, Wilson PWF, Selhub J: Hyperhomocysteinemia and traditional cardiovascular disease risk factors in end-stage renal disease patients on dialysis: a case-control study. Atherosclerosis 1995, 114:93-103.
11. Robinson K, Gupta A, Dennis VW, Arheart K, Chaudhary D, Green R, Vigo P, Mayer EL, Selhub J, Kutner M, Jacobsen D: Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations. Circulation 1996, 94:2743-2748. This is an extensive and comprehensive analysis of the problem of hyperhomocysteinemia in ESRD patients.
12. Garg UC, Zheng ZJ, Folsom AR, Moyer YS, Tsai MY, McGovern P, Eckfeldt JH: Short-term and long-term variability of plasma homocysteine measurement. Clin Chem 1997, 43:141-145.
13. Bachmann J, Tepel M, Raidt H, Riezler R, Graefe U, Langer K, Zidek W: Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 1995, 6:121-125.
14. Goyette P, Christensen B, Rosenblatt DS, Rozen R: Severe and mild mutations in cis for the methylenetetrahydrofolate reductase (MTHFR) gene, and description of five novel mutations in MTHFR. Am J Hum Genet 1996, 59:1268-1275.
15. Sperandeo MP, Candito M, Sebastio G, Rolland MO, Turc-Carel C, Giudicelli H, Dellamonica P, Andria G: Homocysteine response to methionine challenge in four obligate heterozygotes for homocystinuria and relationship with cystathionine beta-synthase mutations. J Inherit Metab Dis 1996, 19:351-356.
16. Kang SS, Zhou J, Wong PW, Kowalisyn J, Strokosch G: Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase. Am J Hum Genet 1988, 43:414-421.
17. Kang SS, Wong PWK, Susmano A, Sora J, Norusis M, Ruggie N: Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991, 48:536-545.
18. Kang SS, Passen EL, Ruggie N, Wong PW, Sora H: Thermolabile defect of methylenetetrahydrofolate reductase in coronary artery disease. Circulation 1993, 88:1463-1469.
19. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews HG, Boers GJH, den Heijer M, Kluijtmans LAJ, van den Heuvel LP, Rozen R: A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nature Genet 1995, 10:111-113.
20. Kang SS, Wong PW, Susmano A, Sora J, Norusis M, Ruggie N: Thermolabile methylenetetrahydrofolate reductase: an inherited risk factor for coronary artery disease. Am J Hum Genet 1991, 48:536-545.
21. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R: Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 1996, 93:7-9. The strong association between hyperhomocysteinemia, low folate and homozygosity for thermolabile MTHFR indicate that the mutated enzyme might not be under normal regulation.
22. Harmon DL, Woodside JV, Yarnell JW, McMaster D, Young IS, McCrum EE, Gey KF, Whitehead AS, Evans AE: The common 'thermolabile' variant of methylene tetrahydrofolate reductase is a major determinant of mild hyperhomocysteinaemia. Q J Med 1996, 89:571-577.
23. Guttormsen AB, Ueland PM, Nesthus I, Nygard O, Schneede J, Vollset SE, Refsum H: Determinants and vitamin responsiveness of intermediate hyperhomocysteinemia (> or = 40 micromol/liter). The Hordaland Homocysteine Study. J Clin Invest 1996, 98:2174-2183. Based on the Hordaland Homocysteine Study, the authors identified a group with intermediate homocysteine levels who responded to a low dose of folic acid with substantial reduction and even normalization of their elevated homocysteine levels.
24. Schmitz C, Lindpaintner K, Verhoef P, Gaziano JM, Buring J: Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction. A case-control study. Circulation 1996, 94:1812-1814.
25. Ma J, Stampfer MJ, Hennekens CH, Frosst P, Selhub J, Horsford J, Malinow MR, Willett WC, Rozen R: Methylenetetrahydrofolate reductase polymorphism, plasma tolate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996, 94:2410-2416. The highlight of this study was the lack of increased risk for myocardial infarction associated with MTHFR polymorphism, in spite of higher homocysteine levels.
26. Gallagher PM, Meleady R, Shields DC, Tan KS, McMaster D. Rozen R, Evans A, Graham IM, Whitehead AS: Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. Circulation 1996, 94:2154-2158.
27. van Bockxmeer FM, Mamotte CD, Vasikaran SD, Taylor RR: Methylenetetrahydrofolate reductase gene and coronary artery disease. Circulation 1997, 95:21-23.
28. Christensen B, Frosst P, Lussier-Cacan S, Selhub J, Goyette P, Rosenblatt DS, Genest J, Rozen R: Correlation ot a common mutation in the methylenetetrahydrofolate reductase gene with plasma homocysteine in patients with premature coronary artery disease. Arterioscler Thromb Vasc Biol 1997, 17:569-573.
29. Nygard O, Refsum H, Ueland PM, Stensvold I, Nordrehaug JE, Kvale G, Vollset SE: Coffee consumption and plasma total homocysteine: the Hordaland Homocysteine Study. Am J Clin Nutr 1997, 65:136-143.
30. Arnadottir M, Hultberg B, Vladov V, Nilsson-Ehle P, Thysell H: Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation 1996, 61:509-512.
31. Matthias D, Becker CH, Riezler R, Kindling PH: Homocysteine induced arteriosclerosis-like alterations of the aorta in normotensive and hypertensive rats following application of high doses of methionine. Atherosclerosis 1996, 122:201-216. The direct angiotoxic effects of homocysteine are again demonstrated. The more pronounced effects observed in spontaneous hypertensive rats suggest an interrelation between cardiovascular risk factors.
32. Lentz SR, Sobey CG, Piegors DJ, Bhopatkar MY, Faraci FM, Malinow MR, Heistad DD: Vascular dysfunction in monkeys with diet-induced hyperhomocyst(e)inemia. J Clin Invest 1996, 98:24-29 This study provides in-vivo data that hyperhomocystinemia alters endothelial and vascular function without morphologic changes. In addition to altered vasoactive responsiveness, thrombomodulin anticoagulant activity was decreased.
33. Tawakol A, Omland T, Gerhard M, Wu JT, Creager MA: Hyperhomocyst(e)inemia is associated with impaired endothelium-dependent vasodilation in humans. Circulation 1997, 95:1119-1121.
34. Upchurch GR Jr, Welch GN, Loscalzo J: Homocysteine, EDRF, and endothelial function. J Nutr 1996, 126(suppl):1290S-1294S.
35. Loscalzo J: The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996, 98:5-7.
36. Blundell G, Jones BG, Rose FA, Tudball N: Homocysteine mediated endothelial cell toxicity and its amelioration. Atherosclerosis 1996, 122:163-172.
37. Kokame K, Kato H, Miyata T: Homocysteine-respondent genes in vascular endothelial cells identified by differential display analysis. GRP78/BiP and novel genes. J Biol Chem 1996, 271:29659-29665. This study shows direct effects of homocysteine on endothelial cells and their gene regulation. It extends the range of mechanisms by which homocysteine might disturb cellular metabolism.
38. Tsai JC, Wang H, Perrella MA, Yoshizumi M, Sibinga NE, Tan LC, Haber E, Chang TH, Schlegel R, Lee ME: Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest 1996, 97:146-153.
39. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R, Lee ME: Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci U S A 1994, 91:6369-6373
40. Lubec B, Labudova O, Hoeger H, Muehl A, Fang-Kircher S, Marx M, Mosgoeller W, Gialamas J: Homocysteine increases cyclin-dependent kinase in aortic rat tissue. Circulation 1996, 94:2620-2625.
41. Lubec B, Arbeiter K, Hoeger H, Lubec G: Increased cyclin dependent kinase in aortic tissue of rats fed homocysteine. Thromb Haemost 1996, 75:542-545.
42. van der Molen EF, van den Heuvel LP, te Poele Pothoff MT, Monnens IA, Eskes TK, Blom HJ: The effect of folic acid on the homocysteine metabolism in human umbilical vein endothelial cells (HUVECs). Eur J Clin Invest 1996, 26:304-309.
43. Arnadottir M, Hultberg B, Nilsson-Ehle P, Thysell H: The effect of reduced glomerular filtration rate on plasma total homocysteine concentration. Scand J Clin Lab Invest 1996, 56:41-46.
44. Guttormsen AB, Mansoor AM, Fiskerstrand T, Ueland PM, Refsum H: Kinetics of plasma homocysteine in healthy subjects after peroral homocysteine loading. Clin Chem 1993, 39:1390-1397.
45. Wilcken DEL, Dudman NPB, Tyrrell PA, Robertson MR: Folic acid lowers elevated plasma homocysteine in chronic renal insufficiency: possible implications for prevention of vascular disease. Metabolism 1988, 37:697-701.
46. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, Bendich A, Selhub J, Rosenberg IH: High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996, 49:147-152.
47. Chauveau P, Chadefaux B, Coude M, Aupetit J, Kamoun P, Jungers P: Long-term folic acid (but not pyridoxine) supplementation lowers elevated plasma homocysteine level in chronic renal failure. Miner Electrolyte Metab 1996, 22:106-109.
48. Bostom AG, Shemin D, Lapane KL, Nadeau MR, Sutherland P, Chan J, Rozen R, Yoburn D, Jacques PF, Selhub J, Rosenberg IH: Folate status is the major determinant of fasting total plasma homocysteine levels in maintenance dialysis patients. Atherosclerosis 1996, 123:193-202.